Recent Updates
Recently added Catalysts

Congenital Adrenal Hyperplasia: 3 biotech companies with clinical-stage programmes

Congenital Adrenal Hyperplasia - 21-Hydroxylase Deficiency.Cardiovascular & MetabolicConcentrated betData as of 2026-09-04

Competitors3in the clinic
Median market cap$14.7Buniverse median $1.20B
Allocated capital$14.6B$39.8B competing
Phase 3 or filed20 mid, 1 early
Pure plays0this indication only
Capital rank5/299crowding rank 55

Congenital Adrenal Hyperplasia is a concentrated bet: only 3 US-listed developers are in the clinic, and the median one is worth $14.7B against a $1.20B universe median.

Scarcity is doing the work in that number. A thin field means an approval is shared with fewer rivals, and the market pays a premium for that position.

2 of the 3 are in Phase 3 or filed, and 1 dated catalyst falls in the next 12 months, so this ranking is likely to move.

$14.6B of allocated capital sits in Congenital Adrenal Hyperplasia, ranking it 5th of 299 indications by the money committed to it.

Companies developing drugs for Congenital Adrenal Hyperplasia 3

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
NBIXNeurocrine BiosciencesCrinecerfontPhase 34$16.1BNo6 31 Dec 2027
CRNXCrinetics PharmaceuticalsatumelnantPhase 33$9.0BNo2No dated event
BBIOBridgeBio PharmaAAV BBP-631Phase 11$14.7BNo2 27 Nov 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile. NBIX holds 40% of the $39.8B competing in this indication.

Why Congenital Adrenal Hyperplasia is a concentrated bet

Few competitors, each one large. The market pays a scarcity premium to compete here.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Congenital Adrenal Hyperplasia has 3 competitors and a median of $14.7B.

Cardiovascular & Metabolic

Cardiovascular & Metabolic holds $89.7B of the map's capital, 13.4% of the total, spread across 29 indications and 44 companies. 9 of those indications have more than one company competing.

See every Cardiovascular & Metabolic indication on the map

Related indications in Cardiovascular & Metabolic

Obesity9 companies · $13.1B · median $2.4BGold rushMASH (NASH)4 companies · $19.4B · median $12.2BConcentrated betPulmonary Arterial Hypertension3 companies · $7.1B · median $585MOrphan cornerHypertrophic Cardiomyopathy4 companies · $5.2B · median $2.8BConcentrated betVasomotor Symptoms1 company · $3.5B · median $3.5BUncontestedDiabetes9 companies · $3.2B · median $401MKnife fightHypertriglyceridemia2 companies · $2.8B · median $10.9BConcentrated betChronic Heart Failure With Reduced Ejection Fraction1 company · $2.3B · median $9.2BUncontested

Congenital Adrenal Hyperplasia pipeline questions

Which biotech companies are developing drugs for Congenital Adrenal Hyperplasia?

Neurocrine Biosciences (NBIX, Crinecerfont, Phase 3); Crinetics Pharmaceuticals (CRNX, atumelnant, Phase 3); BridgeBio Pharma (BBIO, AAV BBP-631, Phase 1). Those are the 3 US-listed developers in the $100M to $20B market cap band with a clinical-stage programme in Congenital Adrenal Hyperplasia.

How advanced is the Congenital Adrenal Hyperplasia pipeline?

Of the 3 clinical-stage programmes in Congenital Adrenal Hyperplasia, 2 are in Phase 3 or filed, 0 are in mid-stage development and 1 is in early-stage development.

How much is the typical Congenital Adrenal Hyperplasia biotech company worth?

The median company developing a drug for Congenital Adrenal Hyperplasia is worth $14.7B, against a median of $1.20B across the whole universe. $14.6B of allocated capital sits in the indication, ranking it 5th of 299.

When is the next Congenital Adrenal Hyperplasia catalyst?

The next dated catalyst in Congenital Adrenal Hyperplasia is BBIO on 27 Nov 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map